Australia’s active vaccine safety system

Meningococcal B vaccine 2020

From July 2020 a meningococcal B vaccine, Bexsero®, is being funded under the National Immunisation Program for Aboriginal and Torres Strait Islander children at 2, 4, and 12 months of age (with a catch up program for Aboriginal and Torres Strait Islander children aged under 2 years until 30 June 2023), and people of all ages with specified medical risk conditions that increase their risk of invasive meningococcal disease.

AusVaxSafety is monitoring the safety of Bexsero vaccine. The current reported event rates are consistent with what are expected according to the existing data.

  • < 2 years Meningococcal B vaccine surveillance data

    AusVaxSafety is monitoring the safety of Bexsero vaccine. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

     

    Last updated 20/11/2020

    3,693 Parents/carers responded to an SMS about their child’s health a
    few days after their MenB vaccinations.

    82.5%
    reported no adverse events

    82.5%
    reported no adverse events


    17.5%
    reported any adverse
    event, including...


    1.2%
    who reported taking their child
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    646 parents/carers reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived.

  • 2+ years Meningococcal B vaccine surveillance data

    AusVaxSafety is monitoring the safety of Bexsero vaccine. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

     

    Last updated 20/11/2020

    684 Parents/carers responded to an SMS about their health a
    few days after their MenB vaccinations.

    81.6 %
    reported no adverse events

    81.6 %
    reported no adverse events


    18.4%
    reported any adverse
    event, including...


    1.0%
    who reported taking their child
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    126 parents/carers reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived.